Published in Gene Therapy Weekly, June 2nd, 2005
According to recent research from England, "The activation of NF-kappa B and phosphatidylinositol-3 (PI3) kinase by TNF-alpha and TRAIL overrides the pro-apoptotic effects of these ligands in carcinoma cells and hinders their therapeutic application.
"In this report we show that CD40 ligand, another member of the TNF superfamily, also triggers the activation of these signaling pathways but, importantly, utilizes only the PI3 kinase cascade for anti-apoptotic responses, inasmuch as suppression of PI3 kinase but not NF-kappa B sensitizes carcinoma cells to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.